Journal of Neuro-Oncology

, Volume 104, Issue 2, pp 621–622 | Cite as

The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma

  • Gianluca Marucci
Letter to the Editor


In 2007 the WHO Classification of Tumours of the Central Nervous System introduced the entity “glioblastoma with oligodendroglioma component” (GBM/OLIGO). This entity accounts for approximately one in every ten new glioblastomas (GBM). In practice, those mixed gliomas with necrosis which were previously diagnosed as anaplastic oligoastrocytoma (AOA) are now designated glioblastoma with oligodendroglioma component. In this way we diagnose as glioblastomas some tumours we already know for which survival is longer than for “classic” glioblastomas. Oncologists should be aware that some newly diagnosed cases of GBM, specifically those called GBM/OLIGO, may behave as AOA. In the next few years we could observe two consequences of this: first, if anaplastic oligoastrocytomas with necrosis are now to be diagnosed as glioblastomas with oligodendroglioma component, obviously it must be expected that the incidence of glioblastoma will increase in these years; second, because these tumours with known longer median OS are now included in the group of glioblastomas, improvement in the survival of patients with glioblastoma in the next few years should be ascribed not only to advances in diagnosis and treatment but also to a semantic factor.


Glioblastoma Anaplastic oligoastrocytoma Incidence Survival Neuro-oncology 


  1. 1.
    Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20(4):E1PubMedCrossRefGoogle Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World health organization classification of tumours of the central nervous system. IARC Press, LyonGoogle Scholar
  3. 3.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  4. 4.
    Salvati M, Formichella AI, D’Elia A et al (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94:129–134PubMedCrossRefGoogle Scholar
  5. 5.
    Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419–5426PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.Sezione di Anatomia Patologica “M. Malpighi”, Ospedale BellariaBolognaItaly

Personalised recommendations